Top

Published in:

Open Access 01-12-2017 | Research article

Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile

Authors: Priscilla Brebi, Carmen Gloria Ili, Alejandra Andana, Doris Menzel, Jaime Lopez, Pablo Guzman, Angelica Melo, Kurt Buchegger, Juan C. Roa

Published in: BMC Cancer | Issue 1/2017

Abstract

Background

Human papillomavirus (HPV) is the etiological factor for cervical cancer and its precursor lesions. The characterization of HPV genotypes in preneoplastic lesions and cervical cancer could establishes the effectiveness of vaccination plan in Chilean population. The aim of this study was to determine HPV frequency in a group of women including in a cervical screening program in the public health care system in Chile.

Methods

We analyzed 985 cervical smears samples from women with different histological diagnosis, attending to public health care in Temuco-Chile between 2004 and 2012, to detect HPV genotypes, through PCR followed by reverse line blotting assay.

Results

HPV was found present in 80.8% (n = 796) of samples. Only a 5.6% of 985 samples were infected with a low-risk HPV, considering multiple infections. 10.5% (n = 8/76) of normal cervical epithelia, 83.5% (n = 208/249) and 87.6% (n = 557/636) of low and high grade squamous intraepithelial lesions, respectively, and 95.8% (n = 23/24) of squamous cervical carcinomas tested positive for HPV. HPV 16 was the most frequent genotype found (Overall 44.9%, n = 442/985; SCC: 62.5%, n = 15/24). A high variability of HPV types was also found in preneoplastic lesions, whereas there was a selection of genotypes in neoplasia. Also, there was a higher risk of infection with HPV 16 in women ≤26 years and 34–41 years old (p < 0.05), meanwhile infections with HPV 16 or HPV 18 have related with cancer development (p < 0.01).

Conclusions

These data provide further information about the frequency of HPV genotypes in women with cervical lesions in Chile, and the introduction of new targeted vaccines against a wider spectrum of HPV is suggested.

Available only for authorised users

Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11–22.CrossRefPubMed

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed

Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89(1):101–5.CrossRefPubMedPubMedCentral

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed 15 Sept 2015.

Ferreccio C, Prado RB, Luzoro AV, Ampuero SL, Snijders PJ, Meijer CJ, Vaccarella SV, Jara AT, Puschel KI, Robles SC, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomark Prev. 2004;13(12):2271–6.

Ili CG, Brebi P, Lopez J, Garcia P, Leal P, Suarez E, Roa JC. Genotyping of human papillomavirus in cervical intraepithelial neoplasia in a high-risk population. J Med Virol. 2011;83(5):833–7.CrossRefPubMed

Bruni L, Barrionuevo-Rosas L, Serrano B, Brotons M, Cosano R, Muñoz J, Bosch FX, de Sanjosé S, Castellsagué X. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Americas. 2014. Available: http://www.hpvcentre.net/statistics/reports/XMX.pdf. Accessed 4 Apr 2014.

Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278–85.CrossRefPubMed

10.

Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci. 2004;50(1–2):9–19.PubMed

11.

Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17.CrossRefPubMedPubMedCentral

12.

Solomon D. The Bethesda System for reporting cervical/vaginal cytologic diagnosis: an overview. Int J Gynecol Pathol. 1991;10(4):323–5.CrossRefPubMed

13.

Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Can Med Assoc J. 2001;164(7):1017–25.

14.

Huang SL, Chao A, Hsueh S, Chao FY, Huang CC, Yang JE, Lin CY, Yan CC, Chou HH, Huang KG, et al. Comparison between the Hybrid Capture II Test and an SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J Clin Microbiol. 2006;44(5):1733–9.CrossRefPubMedPubMedCentral

15.

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst. 2006;98(2):92–100.CrossRefPubMed

16.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. J Am Med Assoc. 2002;288(14):1749–57.CrossRef

17.

Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis Markers. 2007;23(4):273–81.CrossRefPubMedPubMedCentral

18.

Goodman A. HPV testing as a screen for cervical cancer. BMJ. 2015;350:h2372.CrossRefPubMed

19.

Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366(9490):991–8.CrossRef

20.

Aedo S, Melo A, Garcia P, Guzman P, Capurro I, Roa JC. Detection and typification of human papilloma virus in pre cancerous cervical lesions. Rev Med Chil. 2007;135(2):167–73.CrossRef

21.

Melo A, Montenegro S, Hooper T, Capurro I, Roa JC, Roa I. Human papilloma virus (HPV) typing in preneoplastic and neoplastic lesions of the uterine cervix in the IX region-Chile. Rev Med Chil. 2003;131(12):1382–90.CrossRefPubMed

22.

Roa JC, Garcia P, Gomez J, Fernandez W, Gaete F, Espinoza A, Lepetic A, Suarez E. HPV genotyping from invasive cervical cancer in Chile. Int J Gynaecol Obstet. 2009;105(2):150–3.CrossRefPubMed

23.

Valdivia LI, Aguayo GF, Pruyas AM, Snijders PJ, Corvalan RA, Ferreccio RC. Human papillomavirus (HPV) genotypes in cervix uterine cancer patients in a public hospital and private clinic from Santiago, Chile. Rev Chil Infectol. 2010;27(1):11–6.CrossRef

24.

van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40(3):779–87.CrossRefPubMedPubMedCentral

25.

Gravitt PE, van Doorn LJ, Quint W, Schiffman M, Hildesheim A, Glass AG, Rush BB, Hellman J, Sherman ME, Burk RD, et al. Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J Clin Microbiol. 2007;45(10):3245–50.CrossRefPubMedPubMedCentral

26.

Melo A, Roa I, Montenegro S, Capurro I, Roa JC. Detection of human papilloma virus in cytologic samples or biopsies of the cervix. Rev Med Chil. 2005;133(6):639–44.CrossRefPubMed

27.

Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomark Prev. 2005;14(5):1157–64.CrossRef

28.

Garcia P, Benavente F, Melo A, Roa I, Roa J. Effect of fixation on DNA quality: controlled study with five fixatives. Rev Esp Patol. 2006;39:175–9.

29.

Santos C, Munoz N, Klug S, Almonte M, Guerrero I, Alvarez M, Velarde C, Galdos O, Castillo M, Walboomers J, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer. 2001;85(7):966–71.CrossRefPubMedPubMedCentral

30.

Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care. 2006;12(17 Suppl):S462–72.PubMed

31.

Quint W, Jenkins D, Molijn A, Struijk L, van de Sandt M, Doorbar J, Mols J, Van Hoof C, Hardt K, Struyf F, et al. One virus, one lesion--individual components of CIN lesions contain a specific HPV type. J Pathol. 2012;227(1):62–71.CrossRefPubMed

32.

Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63–73.CrossRefPubMedPubMedCentral

33.

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(Suppl 10):K1–16.CrossRefPubMed

34.

Chakrabarti O, Krishna S. Molecular interactions of ‘high risk’ human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression. J Biosci. 2003;28(3):337–48.CrossRefPubMed

35.

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.CrossRefPubMed

36.

Lagos M, Van De Wyngard V, Poggi H, Cook P, Viviani P, Barriga MI, Pruyas M, Ferreccio C. HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile. Infect Agents Cancer. 2015;10:43.CrossRefPubMedPubMedCentral

37.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926–35.CrossRefPubMed

38.

Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119(11):2677–84.CrossRefPubMed

39.

Luu HN, Adler-Storthz K, Dillon LM, Follen M, Scheurer ME. Comparing the Performance of Hybrid Capture II and Polymerase Chain Reaction (PCR) for the Identification of Cervical Dysplasia in the Screening and Diagnostic Settings. Clin Med Insights Oncol. 2013;7:247–55.CrossRefPubMedPubMedCentral

Title: Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile
Authors: Priscilla Brebi
Carmen Gloria Ili
Alejandra Andana
Doris Menzel
Jaime Lopez
Pablo Guzman
Angelica Melo
Kurt Buchegger
Juan C. Roa
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-017-3496-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder

Hybrid peripheral nerve sheath tumors: report of five cases and detailed review of literature

Preoperative T staging using CT colonography with multiplanar reconstruction for very low rectal cancer

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery

Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer